Novartis Increases Sales but Misses Estimates on Earnings
Novartis (SWX: NOVN) reported earnings on Jan. 23. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Novartis beat expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue was unchanged and GAAP earnings per share increased significantly.
Gross margins dropped, operating margins dropped, net margins expanded.
Novartis logged revenue of $14.83 billion. The 13 analysts polled by S&P Capital IQ expected revenue of $14.49 billion on the same basis. GAAP reported sales were 0.5% higher than the prior-year quarter's $15.00 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.27. The nine earnings estimates compiled by S&P Capital IQ predicted $1.31 per share. GAAP EPS of $0.83 for Q4 were 69% higher than the prior-year quarter's $0.49 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 66.2%, 240 basis points worse than the prior-year quarter. Operating margin was 16.5%, 400 basis points worse than the prior-year quarter. Net margin was 13.6%, 580 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $13.50 billion. On the bottom line, the average EPS estimate is $1.40.
Next year's average estimate for revenue is $57.02 billion. The average EPS estimate is $5.27.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Novartis is outperform, with an average price target of $65.91.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Novartis. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Novartis to My Watchlist.
The article Novartis Increases Sales but Misses Estimates on Earnings originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.